RSV disease in infants and young children: Can we see a brighter future?

RSV disease in infants and young children: Can we see a brighter future?

Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children &l...

Full description

Bibliographic Details
Main Authors:	Eugenio Baraldi, Giovanni Checcucci Lisi, Claudio Costantino, Jon H. Heinrichs, Paolo Manzoni, Matteo Riccò, Michelle Roberts, Natalya Vassilouthis
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-11-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	rsv all infants respiratory syncytial virus rsv rsv epidemiology rsv paediatric burden rsv prevention lrti rsv vaccines monoclonal antibodies
Online Access:	http://dx.doi.org/10.1080/21645515.2022.2079322

Similar Items

Epidemiology and prevention of respiratory syncytial virus infections in children in Italy
by: Chiara Azzari, et al.
Published: (2021-10-01)

Respiratory Syncytial Virus Prevention through Monoclonal Antibodies: A Cross-Sectional Study on Knowledge, Attitudes, and Practices of Italian Pediatricians
by: Matteo Riccò, et al.
Published: (2023-02-01)

Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States
by: Mark H. Rozenbaum, et al.
Published: (2023-01-01)

RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
by: Paulina Dąbrowska, et al.
Published: (2024-02-01)

Epidemiology and molecular characteristics of respiratory syncytial virus (RSV) among italian community-dwelling adults, 2021/22 season
by: Donatella Panatto, et al.
Published: (2023-03-01)

Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors
by: Nijolė Drazdienė, et al.
Published: (2018-08-01)

Psychometric evaluation of the respiratory syncytial virus infection, intensity and impact questionnaire (RSV-iiiQ) in adults
by: Valerie Williams, et al.
Published: (2024-02-01)

Respiratory Syncytial Virus Matrix Protein Is Sufficient and Necessary to Remodel Host Mitochondria in Infection
by: MengJie Hu, et al.
Published: (2023-05-01)

Dominance of the ON1 Genotype of RSV-A and BA9 Genotype of RSV-B in Respiratory Cases from Jeddah, Saudi Arabia
by: Hessa A. Al-Sharif, et al.
Published: (2020-11-01)

Human Respiratory Syncytial Virus Epidemiological Burden in Pediatric Outpatients in Italy: A Systematic Review
by: Sara Boccalini, et al.
Published: (2023-09-01)

Assessing the patient experience of respiratory syncytial virus infection: development of a patient-reported outcome measure
by: Carla (DeMuro) Romano, et al.
Published: (2023-02-01)

Mutation of Respiratory Syncytial Virus G Protein’s CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells
by: Binh Ha, et al.
Published: (2019-07-01)

Burden of respiratory syncytial virus infections in China: Systematic review and meta–analysis
by: Yaowen Zhang, et al.
Published: (2015-12-01)

RSV awareness, risk perception, causes, and terms: Comment
by: Somsri Wiwanitkit, et al.
Published: (2023-12-01)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
by: Gwenaelle Mulot, et al.
Published: (2022-07-01)

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study
by: Chiara Ratti, et al.
Published: (2023-01-01)

RSV: perspectives to strengthen the need for protection in all infants
by: Jose Antonio Navarro Alonso, et al.
Published: (2021-10-01)

Non-Coding RNAs and Their Role in Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Infections
by: Wenzhe Wu, et al.
Published: (2020-03-01)

IFN-γ Attenuates Eosinophilic Inflammation but Is Not Essential for Protection against RSV-Enhanced Asthmatic Comorbidity in Adult Mice
by: Abenaya Muralidharan, et al.
Published: (2022-01-01)

All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?
by: Sofie Schaerlaekens, et al.
Published: (2024-01-01)

Molecular Mimicry between Respiratory Syncytial Virus F Antigen and the Human Proteome
by: Darja Kanduc
Published: (2023-01-01)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
by: Freek Cox, et al.
Published: (2023-03-01)

Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies
by: Lotte Jacobs, et al.
Published: (2023-09-01)

Epidemiology and molecular analyses of respiratory syncytial virus in the 2021–2022 season in northern Italy
by: Alessia Lai, et al.
Published: (2024-01-01)

Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update
by: Yaneisi Vázquez, et al.
Published: (2019-06-01)

Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities
by: Peter Mastrangelo, et al.
Published: (2017-09-01)

Clinical comparison of HMPV and RSV infections in hospitalised Malaysian children: A propensity score matched study
by: David Chun‐Ern Ng, et al.
Published: (2024-03-01)

Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
by: Jackelyn Murray, et al.
Published: (2022-04-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)

Probing In Silico the Benzimidazole Privileged Scaffold for the Development of Drug-like Anti-RSV Agents
by: Elena Cichero, et al.
Published: (2021-12-01)

Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
by: Carlotta Biagi, et al.
Published: (2020-11-01)

Human respiratory syncytial virus and coronavirus rates in Iranian elderly patients more than 60 years old with acute respiratory symptoms
by: Shaian Tavakolian, et al.
Published: (2023-01-01)

Seroepidemiology of Respiratory Syncitial Virus and Influenza Viruses in Cases with Severe Chronic Obstructive Pulmonary Disease
by: Gülru ERBAY, et al.
Published: (2014-12-01)

Relationship between neighborhood census-tract level socioeconomic status and respiratory syncytial virus-associated hospitalizations in U.S. adults, 2015–2017
by: Jenna E. Holmen, et al.
Published: (2021-03-01)

The assessment of future RSV immunizations: How to protect all infants?
by: Louis Bont, et al.
Published: (2022-08-01)

Early-Life Lung and Gut Microbiota Development and Respiratory Syncytial Virus Infection
by: Kazuma Yagi, et al.
Published: (2022-04-01)

Development of Inhalable Chitosan-Coated Oxymatrine Liposomes to Alleviate RSV-Infected Mice
by: Jianqing Peng, et al.
Published: (2022-12-01)

Maternal RSV vaccine development. Where to from here?
by: Ahinsa Gunatilaka, et al.
Published: (2021-11-01)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
by: Tyler Brady, et al.
Published: (2023-10-01)

Unbiased analysis of peripheral blood mononuclear cells reveals CD4 T cell response to RSV matrix protein
by: Juilee Thakar, et al.
Published: (2020-08-01)